Arbutus Net Tangible Assets from 2010 to 2026
| ABUS Stock | USD 3.98 0.03 0.75% |
Net Tangible Assets | First Reported 2000-03-31 | Previous Quarter 143.9 M | Current Value 134.7 M | Quarterly Volatility 112.4 M |
Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 149.7 K or Selling General Administrative of 26.7 M, as well as many indicators such as Price To Sales Ratio of 92.94, Dividend Yield of 0.0424 or PTB Ratio of 7.98. Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.
Arbutus | Net Tangible Assets | Build AI portfolio with Arbutus Stock |
The evolution of Net Tangible Assets for Arbutus Biopharma Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Arbutus Biopharma compares to historical norms and industry peers.
Latest Arbutus Biopharma's Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Arbutus Biopharma Corp over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Arbutus Biopharma's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arbutus Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Arbutus Net Tangible Assets Regression Statistics
| Arithmetic Mean | 111,734,612 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 124.01 | |
| Mean Deviation | 91,810,481 | |
| Median | 132,693,000 | |
| Standard Deviation | 138,557,600 | |
| Sample Variance | 19198.2T | |
| Range | 612.2M | |
| R-Value | 0.18 | |
| Mean Square Error | 19840.9T | |
| R-Squared | 0.03 | |
| Significance | 0.50 | |
| Slope | 4,840,078 | |
| Total Sum of Squares | 307171.3T |
Arbutus Net Tangible Assets History
About Arbutus Biopharma Financial Statements
Arbutus Biopharma shareholders use historical fundamental indicators, such as Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Arbutus Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 157.4 M | 165.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.